Lupin rolls out Rufinamide Tablets USP in the US market

6 Dec 2022 , 10:59 AM

Lupin Limited, a global pharmaceutical company, announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, as a generic equivalent to Eisai Inc.’s Banzel Tablets, 200 mg, and 400 mg.

In the United States, Rufinamide Tablets (RLD Banzel) had an estimated annual sales of USD 138 million (IQVIA MAT October 2022).

Rufinamide is an anticonvulsant medication that is used in conjunction with other medications and therapy to treat Lennox-Gastaut syndrome and other seizure disorders.

Eisai manufactures the drug, which was developed by Novartis Pharma, AG in 2004.

Lupin is the third-largest pharma company in the United States in terms of prescriptions. In FY22, the company spent 8.7% of its revenue on research and development.

At around 11.02 AM, Lupin was trading at Rs764 down by 0.79% from its previous closing of Rs770.10 on the BSE. The scrip opened at Rs762.05 and touched intraday high and low of Rs769.70 and Rs762.05 respectively.

For feedback and suggestions, write to us at [e-mail]